Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

doi:10.1056/NEJMoa1713137

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

The New England journal of medicine - 11 Jan 2018

Soria Jean-Charles, Ohe Yuichiro, Vansteenkiste Johan, Reungwetwattana Thanyanan, Chewaskulyong Busyamas, Lee Ki Hyeong, Dechaphunkul Arunee, Imamura Fumio, Nogami Naoyuki, Kurata Takayasu, Okamoto Isamu, Zhou Caicun, Cho Byoung Chul, Cheng Ying, Cho Eun Kyung, Voon Pei Jye, Planchard David, Su Wu-Chou, Gray Jhanelle E, Lee Siow-Ming, Hodge Rachel, Marotti Marcelo, Rukazenkov Yuri, Ramalingam Suresh S

Abstract excerpt

BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS: In this double-blind,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Double-Blind Method

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 29151359
DOI: 10.1056/NEJMoa1713137

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.PMID 29151359Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.Semantic proximity Read ↗

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.Semantic proximity Read ↗

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.